USPTO serial 79197165
CAP GO
Reviewed by CopyMark Law Group
Reg. 5343212Status 709
- Filing date
- Status date
- Registration date
- Nov 28, 2017
- Examiner
- MIDDLETON, BERNICE L
- Law office
- TMEG LAW OFFICE 106
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CAP GO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Sheridan Ross P.C.1560 Broadway, Suite 1200Denver, CO 80202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological and biochemical products, preparations and reagents for scientific, research, laboratory, industrial and commercial purposes, except chromatography chemicals and media, and except chemicals for use in separation and purification; chemical, biological and biochemical products, preparations and reagents for researching and characterizing diseases except chromatography chemicals and media, and except chemicals for use in separation and purification; chemical, biological and biochemical products, preparations and reagents for scientific and medical research and drug development except chromatography chemicals and media, and except chemicals for use in separation and purification; chemical, biological and biochemical products, preparations and reagents for manufacturing drugs and pharmaceuticals, except chromatography chemicals and media, and except chemicals for use in separation and purification; micro-organisms, proteins, polypeptides, nucleotides, nucleic acids, eukaryotic cell lines and eukaryotic cells for scientific, research, laboratory, industrial and commercial purposes; all other than for medical or veterinary use | SECTION 71 - CANCELLED | — |
| 005 | Medicines for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except thyreostatics and cough and cold preparations; pharmaceutical and veterinary products, preparations and reagents for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, all afore mentioned goods except thyreostatics and cough and cold preparations; chemical, biological and biochemical preparations for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, preparations and reagents for medical and veterinary purposes for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except cough and cold preparations, except chromatography chemicals and media, and except chemicals for use in separation and purification; diagnostic and analytical preparations for medical and veterinary purposes for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases; cultures of micro-organisms, protein arrays, synthetic polypeptides, nucleotide arrays, nucleic acid sequence, eukaryotic cell lines and eukaryotic cells for medical, veterinary and diagnostic purposes, except cough and cold preparations | SECTION 71 - CANCELLED | — |
| 042 | Scientific and industrial research, in particular in the fields of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures and expression systems; scientific, technical and industrial consultancy, in particular in the field of research medicine, pharmacy, molecular biology, biotechnology and genetics; scientific and industrial research and development of eukaryotic cell lines, eukaryotic cells, micro-organisms, polypeptides, proteins, nucleotides, nucleic acids, for third parties for scientific, research, laboratory development, industrial and commercial purposes, in particular for use in the field of medicine, pharmacy, molecular biology, biotechnology and genetics, except services relating to capture and intermediate purification of proteins | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CEVEC Pharmaceuticals GmbH
- Other trademarks owned by CEVEC Pharmaceuticals GmbH
- Other trademarks owned by CEVEC Pharmaceuticals GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named CAP GO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2025 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 28, 2025 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 28, 2025 | INPC | INVALIDATION PROCESSED | — |
| Feb 14, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 18, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 14, 2024 | C71T | CANCELLED SECTION 71 | — |
| Nov 19, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 21, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 21, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 21, 2023 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Aug 21, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 21, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 21, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 28, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jul 13, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 13, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 13, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 11, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 11, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 11, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 11, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 22, 2018 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Oct 19, 2018 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Aug 23, 2018 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Aug 22, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 17, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 27, 2018 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Apr 27, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 7, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 7, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 28, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 28, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 27, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 12, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 12, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 23, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 1, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 8, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 7, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 7, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 24, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 8, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 8, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 8, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 7, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 2, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 1, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |